BioStock: Mendus presents proof-of-concept data in AML maintenance

Acute myeloid leukaemia relapses easily, leading to a significant decrease in survival chances. Immuno-oncology biotech Mendus is developing a tumour recurrence vaccine, and new positive phase II data presented yesterday at the American Society of Hematology meeting suggest that the company’s candidate DCP-001 is much more effective than current standard of care AML maintenance treatment.

Read the article at biostock.se:

Mendus presents proof-of-concept data in AML maintenance - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/